FDA restricts use of bluebird's gene therapy due to increased cancer risk

The FDA is restricting the use of bluebird bio's rare neurologic disease gene therapy Skysona after the number of cancer diagnoses linked to use of the treatment increased substantially in clinical trial participants since its ...